Vericel Corporation (VCEL)

Vericel Corporation is trading at $44.93, up 3.07% on the session. The 50 day average sits at $43.73 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 46.1, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $43.95 with resistance near $46.62, so that band frames the current range. Average daily movement is roughly $1.62, or about 3.6% of the share price, which is what any stop placement has to allow for. The overall health score of 52 out of 100 combines a trend score of 55, momentum of 36 and a risk score of 69.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.